TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01067898

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D3 (cholecalciferol)
Description: vitamin D3 (cholecalciferol) oil 20 000 IU/ml, oral dose of 200 000 IU or 100 000 IU (10ml or 5ml) every three months for one year.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin D3 (cholecalciferol)
Description: vitamin D3 (cholecalciferol) oil 20 000 IU/ml, oral dose of 200 000 IU or 100 000 IU (10ml or 5ml) every three months for one year.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: olive oil
Description: 10 ml (placebo group) or 5 ml (100 000 IU vitamin D3 group) oil per os every three months for one year

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: olive oil
Description: 10 ml (placebo group) or 5 ml (100 000 IU vitamin D3 group) oil per os every three months for one year

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: calcium carbonate
Description: 1000 mg calcium per os every day for one year

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: calcium carbonate
Description: 1000 mg calcium per os every day for one year

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: calcium carbonate
Description: 1000 mg calcium per os every day for one year
Study: NCT05013242

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoladex
Description: evaluate efficacy of Zoladex in complete 12 week treatment of pain in women suffer from chronic pelvic pain diagnosed as endometriosis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Visanne
Description: valuate efficacy of Dienogest in complete 12 week treatment of pain in women suffer from chronic pelvic pain diagnosed as endometriosis
Study: NCT02862938

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT-501 ECT implant
Description: NT-501 ECT implant will be placed into the vitreous and out of the visual axis of the study eye. The surgical procedure involves making a small incision through the sclera (white part of the eye), inserting the implant and securing it with a suture.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Sham surgery
Study: NCT04239352

Intervention type: DIAGNOSTIC_TEST
Intervention: Pentraxin 3 ; new biomarker
Description: Pentraxin (PTX3) is an inflammatory molecule that belongs to a recently identified, well-known C-reactive protein (CRP) family.~PTX3 plasma levels increase in vascular disorders including myocardial infarction and correlate with small vessel vasculitis and outcome or disease activity.~These biological and clinical features of PTX3 have led us to investigate this molecule in preeclampsia, a syndrome characterized by a prominent vascular component.

Intervention type: DIAGNOSTIC_TEST
Intervention: Pentraxin 3 ; new biomarker
Description: Pentraxin (PTX3) is an inflammatory molecule that belongs to a recently identified, well-known C-reactive protein (CRP) family.~PTX3 plasma levels increase in vascular disorders including myocardial infarction and correlate with small vessel vasculitis and outcome or disease activity.~These biological and clinical features of PTX3 have led us to investigate this molecule in preeclampsia, a syndrome characterized by a prominent vascular component.

Intervention type: DIAGNOSTIC_TEST
Intervention: Lipoprotein-associated phospholipase A2 ; new biomarker
Description: Lp-PLA2 is a recently described and potentially useful plasma biomarker associated with cardiovascular diseases. Because of this effect, we will investigate that preeclampsia also be beneficial.

Intervention type: DIAGNOSTIC_TEST
Intervention: Lipoprotein-associated phospholipase A2 ; new biomarker
Description: Lp-PLA2 is a recently described and potentially useful plasma biomarker associated with cardiovascular diseases. Because of this effect, we will investigate that preeclampsia also be beneficial.
Study: NCT03369626

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: FareWell Program
Description: The FareWell Program is a digitally delivered lifestyle management curriculum, which includes meal planning tools, daily self monitoring, personalized goal setting and bi-weekly live one-on-one health coaching.
Study: NCT01942811

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quit Using Drugs Intervention Trial
Description: The goal of the Quit Using Drugs Intervention Trial (QUIT) is to conduct a small RCT of a primary care clinic-based very brief intervention protocol for reducing the use of illegal drugs and the occurrences of drug-related harm in low-income, racially-diverse patient populations at two 'safety-net' clinics in Los Angeles. The design will emphasize screening, very brief clinician advice, and telephone drug-use health education to reduce 'at risk' drug use and thus interrupt progression from casual or episodic abuse to dependence.
Study: NCT02869893

Intervention type: DRUG
Group type: OTHER
Intervention: Secretin
Study: NCT02036684

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation (PREHAB)
Study: NCT03076515

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nerivio Migra neurostimulation
Description: transcutaneous electrical stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Nerivio Migra
Description: electrical stimulation- shame mode
Study: NCT00057525

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anthrax
Description: Doses will range from 5 _g to 100 _g rPA, and at each dose-level, rPA will either be combined with phosphate-buffered saline (PBS) or adsorbed to Alhydrogel

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Alhdryogel or PBS
Description: Doses will range from 5 _g to 100 _g rPA, and at each dose-level, rPA will either be combined with phosphate-buffered saline (PBS) or adsorbed to Alhydrogel
Study: NCT03942887

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Patients will be intravenously treated with Rituximab 1000mg (or biosimilar) in the first week and receive a 2nd dosage of 1000mg 14 days later. Before every infusion of Rituximab patients will receive intravenous methylprednisolone 100mg together with oral acetaminophen 1000 mg and and intravenous Tavegil 2 mg. At any time during the study, a rituximab biosimilar is allowed as a substitute for the bio-originator rituximab.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Patients will be intravenously treated with Rituximab 1000mg (or biosimilar) in the first week and receive a 2nd dosage of 1000mg 14 days later. Before every infusion of Rituximab patients will receive intravenous methylprednisolone 100mg together with oral acetaminophen 1000 mg and and intravenous Tavegil 2 mg. At any time during the study, a rituximab biosimilar is allowed as a substitute for the bio-originator rituximab.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: endoxan
Description: Patients will be intravenously treated with a total of 6 infusions of cyclophosphamide 500mg every 2 weeks. Before every infusion of cyclophosphamide patients will receive intravenous granisetron to prevent nausea.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Patients are given 1-3 pulses of 500mg methylprednisolone i.v. up to a maximum cumulative dose of 3000mg, taking into account any doses of intravenous methylprednisolone administered within 12 weeks prior to screening.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Patients are given 1-3 pulses of 500mg methylprednisolone i.v. up to a maximum cumulative dose of 3000mg, taking into account any doses of intravenous methylprednisolone administered within 12 weeks prior to screening.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: after intravenous pulse methylprednisolone, oral prednisolone will be given at a dose of 1mg/kg daily and tapered according to the recommendations

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: after intravenous pulse methylprednisolone, oral prednisolone will be given at a dose of 1mg/kg daily and tapered according to the recommendations
Study: NCT03070275

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biocomplex: aBM-MSCs/fibrin glue/collagen fleece
Description: Xeno-free, clinical-grade, autologous alveolar bone marrow mesenchymal stem cells enriched with autologous fibrin glue and loaded into a commercially available collagen fleece.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Two-stage surgical implant placement
Description: Implants are surgically placed on the alveolar crest following a two-stage protocol and the manufacture's guidelines with no adjunctives.
Study: NCT03029455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tezacaftor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tezacaftor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivacaftor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-659 Matching Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VX-659 Matching Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple Combination (TC) Matching Placebos

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple Combination (TC) Matching Placebos
Study: NCT00329745

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix™
Description: Oral administration, 2 doses

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral administration, 2 doses
Study: NCT00212264

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Therapy
Description: Pelvic Floor Muscle Exercises and Bladder control strategies

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Therapy
Description: Pelvic Floor Muscle Exercises and Bladder control strategies

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pelvic Floor Electrical Stimulation
Description: Pelvic Floor Electrical Stimulation daily for 8 weeks
Study: NCT04527484

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SHR-1314
Description: each group subjects will be given different formulations of SHR-1314

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SHR-1314
Description: each group subjects will be given different formulations of SHR-1314
Study: NCT00212264

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Biofeedback
Description: Pelvic Floor Muscle training via biofeedback

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No Treatment
Description: No treatment
Study: NCT04582201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: agenT-797
Description: agenT-797 is an off-the-shelf cell therapy consisting of ≥ 95% allogeneic human unmodified iNKT cells isolated from 1 healthy donor mononuclear cell apheresis unit and expanded ex vivo.
Study: NCT02486172

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Peer support program
Description: Peer support program as an additional service to the routine clinical service
Study: NCT02370056

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 3-dimensional visualization
Description: Subjects are receiving Standard of Care Colectomy for Ulcerative Colitis visualized in 3D mode

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: 2-dimensional visualization
Description: Subjects are receiving Standard of Care Colectomy for Ulcerative Colitis visualized in 2D mode
Study: NCT00953615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thalidomide
Description: Titrate to 400 mg daily for 6 months
Study: NCT03468790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMAB007
Description: the study drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Symbicort
Description: asthma-controlled drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Symbicort
Description: asthma-controlled drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Seretide
Description: asthma-controlled drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Seretide
Description: asthma-controlled drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ventolin
Description: asthma rescue drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ventolin
Description: asthma rescue drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: No active components
Study: NCT04278170

Intervention type: OTHER
Intervention: no attempt was made to patients
Description: no attempt was made to patients
Study: NCT04038164

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dog-Assisted Therapy and pharmacological treatment
Description: The investigators used the CTAC Method (Center of Dog Assisted Therapy) (E Domènec 2012).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dog-Assisted Therapy and pharmacological treatment
Description: The investigators used the CTAC Method (Center of Dog Assisted Therapy) (E Domènec 2012).
Study: NCT03508180

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: INTERVIONNAL
Description: Foot reflexology session (30 minutes) each course of chemotherapy (total 4 courses) during the 4 hours following the first 2 hours of injection + auto-massage done by the patient between each course.~During a session focused on the treatment of nausea / vomiting, the reflexologist will stimulate the reflex zones related to the digestive system in order to calm and stimulate all areas for deep relaxation of the patient.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: CONTROL
Description: None intervention.
Study: NCT02320448

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PIPAC
Study: NCT01734057

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human thrombopoietin (rhTPO); rituximab
Description: patients in recombination treatment group take Rituximab( intravenously ,100 mg weekly for 4 consecutive weeks); in combination with rhTPO( subcutaneously , 300U/kg for 14 consecutive days,followed by flexible treating dosage so as to keep the platelet count above 50×10\^9/L until the 28th day)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Patients in single treatment group take dexamethasone intravenously at 40 mg daily for 4 consecutive days.
Study: NCT03339557

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NexGen
Description: Comparing two conventional designs and one novel design

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NexGen
Description: Comparing two conventional designs and one novel design

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Persona
Description: Comparing two conventional designs and one novel design

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Persona
Description: Comparing two conventional designs and one novel design

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PFC
Description: Comparing two conventional designs and one novel design

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PFC
Description: Comparing two conventional designs and one novel design
Study: NCT01266005

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clevudine
Description: 30mg,QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entecavir
Description: 0.5mg QD
Study: NCT00551525

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 3D-CRT or IMRT 64.8-70.2 Gy to the prostatic fossa begins 12 weeks (+/- 1 week) after Samarium 153 administration. Daily tumor doses of 1.8 - 2.0 Gy per day, 5 days per week x 7-8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Samarium 153
Description: Samarium 153 lexidronam dose 2.0 mCi/kg by IV injection one time within 2 weeks (+/- 3days) after registration.
Study: NCT01308892

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High flavanol chocolate
Description: chocolate high in flavanols

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Low flavanol chocolate
Description: chocolate low in flavanols

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High fat challenge
Description: Milkshake with 95g fat

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: High fat challenge
Description: Milkshake with 95g fat
Study: NCT04012177

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Balanced-energy protein (BEP)
Description: Pregnant women in the intervention arms will receive approximately 800 Kcal/day and around 16-21 gram of protein in a day in the form of ready-to-use supplement.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Balanced-energy protein (BEP)
Description: Pregnant women in the intervention arms will receive approximately 800 Kcal/day and around 16-21 gram of protein in a day in the form of ready-to-use supplement.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Balanced-energy protein (BEP)
Description: Pregnant women in the intervention arms will receive approximately 800 Kcal/day and around 16-21 gram of protein in a day in the form of ready-to-use supplement.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin Tablets
Description: Pregnant women randomized in Arm C will received two doses of 2000 mg of Azithromycin (4 tablets of 500 mg) oral at week 20 and 28 of pregnancy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin Tablets
Description: Pregnant women randomized in Arm C will received two doses of 2000 mg of Azithromycin (4 tablets of 500 mg) oral at week 20 and 28 of pregnancy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Choline Bitartrate
Description: Pregnant women randomized in Arm D will received 450 mg of Choline orally once daily, starting from week 20 weeks of pregnancy until birth outcome

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotinamide
Description: Pregnant women randomized in Arm D will received 100 mg of Nicotinamide orally once daily, starting from week 20 weeks of pregnancy until birth outcome
Study: NCT03113318

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total mediastinal lymph node dissection and pulmonary metastasectomy
Description: Total mediastinal lymph node dissection where all lymph nodes and fatty tissues is removed conjunction with pulmonary metastasectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Only pulmonary metastasectomy
Study: NCT01110408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doripenem
Description: Type=once every 8 hours infused over 60 minutes, Unit=mg,Number=20mg/kg up to 500mg/dose, Form=solution for infusion,Route=intravenous use. At least 3 days of iv doripenem administered every 8 hours immediately after each iv infusion of cefepime placebo for up to 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doripenem placebo
Description: Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 60 minutes immediately following each iv infusion of cefepime for up to 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefepime
Description: Type=once every 8 hours, Unit=mg, Number=50 mg/kg up to 2g/dose, Form=solution for infusion, Route=intravenous use. At least 3 days of iv cefepime administered every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem placebo for up to 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefepime placebo
Description: Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem for up to 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate potassium
Description: Form=suspension or tablets, Route=oral (by mouth), may be administered at the discretion of the investigator once every 12 hours for up to 14 days following IV therapy with doripenem or cefepime.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate potassium
Description: Form=suspension or tablets, Route=oral (by mouth), may be administered at the discretion of the investigator once every 12 hours for up to 14 days following IV therapy with doripenem or cefepime.
Study: NCT05505695

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brace and Exercise Treatment
Description: Schroth exercises, which are a specific exercise method for scoliosis, were given to the experimental group for 8 weeks, different from the control group.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brace Treatment
Description: Among the patients included in the study, those who wore braces but did not agree to exercise constituted the ''Brace Group'' of the study.
Study: NCT05141929

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: web based education
Description: In addition to routine care, web-based education was offered to pregnant women with Gestational Diabetes Mellitus.
Study: NCT03990311

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium Restricted Meals
Description: 2 meals prepared with 2 g /day sodium restriction and adhering to dietary recommendations for a hemodialysis patients (phosphate and potassium restricted/ high protein content) 2 meals per day for first month of meal provision period followed by 1 meal per month in the second meal of meal provision period

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Usual Care
Study: NCT02078596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Divalproex
Description: Patients were randomly assigned to receive divalproex or placebo first, follow by the converse treatment, for six weeks each

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Divalproex
Description: Patients were randomly assigned to receive divalproex or placebo first, follow by the converse treatment, for six weeks each